Smoking cessation: Update

Clinical Pulmonary Medicine

Volumn 20, Issue 3, 2013, Pages 129-136

  Miranda, Juan A Riesco ^a   Ruiz, Carlos A Jiménez ^b   Rebollo, José C Serrano ^b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Talavera de la Reina Hospital   (Spain)

Author keywords

Smoking cessation; Smoking therapy; Tobacco

Indexed keywords

AMFEBUTAMONE; CLONIDINE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINE VACCINE; NICOTINIC AGENT; NORTRIPTYLINE; NOSE SPRAY; VARENICLINE;

ABNORMAL DREAMING; ANTIDEPRESSANT ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; COUGHING; CRYING; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; GROUP THERAPY; HICCUP; HUMAN; INDIGESTION; INHALER; INSOMNIA; META ANALYSIS (TOPIC); MOTIVATIONAL INTERVIEWING; NAUSEA; NICOTINE REPLACEMENT THERAPY; NONHUMAN; NOSE IRRITATION; NOSE SECRETION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN IRRITATION; SMOKING CESSATION; SMOKING CESSATION PROGRAM; SNEEZING; SOCIAL SUPPORT; TOBACCO DEPENDENCE; VACCINATION; VOMITING; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 84877693893     PISSN: 10680640     EISSN: 15365956     Source Type: Journal    
DOI: 10.1097/CPM.0b013e31828fda4c     Document Type: Article

References (48)

1. Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service; 2000.
2. Fiore MC, Jae'n CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service; 2008.
3. Shiffman S. Relapse following smoking cessation: A situational analysis. J Consult Clin Psychol. 1982;50:71-86. (Pubitemid 13108443)
4. Lancaster T, Stead LF. Self-help interventions for smoking cessation. Cochrane Database Syst Rev. 2005;3:CD001118.
5. Civljak M, Sheikh A, Stead LF. Interned-based interventions for smoking cessation. Cochrane Database Syst Rev. 2010;9.
6. Whittaker R, Borland R, Bullen C, et al. Smoking cessation interventions with mobile-phones. Cochrane Database Syst Rev. 2009;4:CD 006611, Review.
7. National Institute for Clinical Excellence (NICE). Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. National Institute for Clinical Excellence Technology Appraisal Guidance N1 39, 2002. Available at: Http://www.nice.org.uk. Accessed August 27, 2008.
8. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004; 3CD000146.
9. Tonnesen P, Norregaard J, Mikkelsen K, et al. Double-bind trial of a nicotine inhaler for smoking cessation. JAMA. 1993;269: 1268-1271. (Pubitemid 23067430)
10. Schneider NG, Olmstead R, Nilsson F, et al. Efficacy of a nicotine inhaler in smoking cessation: A double-blind, placebocontrolled trial. Addiction. 1996;91:1293-1306. (Pubitemid 26315887)
11. Sutherland G, Stapleton JA, Russell MAH, et al. Randomised controlled trial of a nasal nicotine spray in smoking cessation. Lancet. 1992;340:324-329.
12. Sundblad J, Larsson K, Nathell I. High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalisation. Nicotine Tob Res. 2008;10:883-890. (Pubitemid 351974069)
13. Ferry L, Johnston JA. Efficacy and safety of bupropion SR for smoking cessation: Data from clinical trials and five years of postmarketing experience. Int J Clin Pract. 2003;57:224-230. (Pubitemid 36511783)
14. Damaj MI, Carroll FI, Eaton JB, et al. Enantioselective effects of hydroxyl metabolites of bupropion on behaviour and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol. 2004;66:675-682. (Pubitemid 39329267)
15. Roddy E. Bupropion and other non-nicotine pharmacotherapies. BMJ. 2004;328:509-511.
16. Benowitz N, Dempsy D. Pharmacotherapy for smoking cessation during pregnancy. Nicotine Tob Res. 2004;6:S189- S202. (Pubitemid 38678842)
17. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: A doublebind, placebo-controlled, randomised trial. Lancet. 2001;357: 1571-1575. (Pubitemid 32488814)
18. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: A multicentre, randomised study. Eur Heart J. 2003;24:946-955. (Pubitemid 36559988)
19. Hubbard R, Lewis S, West J, et al. Bupropion and the risk of sudden death: A self-control case-series analysis using The Health Improvement Network. Thorax. 2005;60:848-850. (Pubitemid 41475213)
20. Rigotti NA, Thorndike AN, Regan S, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med. 2006;119:1080-1087. (Pubitemid 44834365)
21. David SP, Niaura R, Papandonatos GD, et al. Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res. 2003;5:935-942. (Pubitemid 38029089)
22. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474-3477. (Pubitemid 40664098)
23. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonist for smoking cessation. Cochrane Database Syst Rev. 2011;2:CD006103. Review.
24. Rigotti N, Pipe A, Benowitz N, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized controlled trial. Circulation. 2010;121: 221-229.
25. Tashkin D, Rennard S, Hays T, et al. Effects of varenicline on smoking cessation in mild-to-moderate COPD: A randomized controlled trial. Chest. 2011;139:591-599.
26. Jiménez CA, Ramos A, Cicero A, et al. Characteristics of COPD smokers and effectiveness and safety of smoking cessation medications. Nicotine Tob Res. 2012;14:1035-1039.
27. Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA. 2006;296:64-71.
28. Hajek P, Tønnesen P, Arteaga C, et al. Varenicline in prevention of relapse to smoking: Effect of quit pattern on response to extended treatment. Addiction. 2009;104:1597-1602.
29. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomized open-label trial. Thorax. 2008;63:717-724.
30. Stapleton JA, Watson L, Spirling L, et al. Varenicline in the routine treatment of tobacco dependence: A pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction. 2008;103:146-154. (Pubitemid 350233424)
31. Hughes J, Rennard S, Fingar J, et al. Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: A randomized placebo-controlled trial. Nicotine Tob Res. 2011; 13:955-964.
32. Ebbert J, Croghan I, Schroeder DR, et al. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res. 2009;11:234-239.
33. Ebbert J, Burke MV, Hays T, et al. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res. 2009;11:572-576.
34. Williams KE, Reeves KR. A double-blind study evaluating the long term safety of varenicline for smoking cessation. Current Med Res Opin. 2007;23:793-801. (Pubitemid 46646499)
35. US Food and Drug Administration. The smoking cessation aids varenicline and bupropion: Suicidal ideation and behavior. FDA Newsletter. 2009;2:1-4.
36. Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: A cohort study based on data from the General Practise Database. BMJ. 2009;339:b3805. doi:10.1136 / bmj.b3805.
37. Tonstad S, Davies S, Flammer M, et al. Psychiatric adverse events in randomized double-blind. Placebo-controlled clinical trials of varenicline. Drug Saf. 2010;33:289-301.
38. Singh S, Loke YK, Spangler JG, et al. Risk of serious adverse cardiovascular events associated with varenicline: A systematic review and meta-analysis. CMAJ. 2011;183:1359-1366. doi: 10.1503 / cmaj.110218. Epub 2011 Jul 4. Review.
39. Prochaska J, Hilton JF. Meta-analyses of varenicline use and treatment emergent cardiovascular events. Poster presented at SRNT Meeting, Texas. 2012.
40. Vocci FJ, Chiang CN. Vaccines against nicotine: How effective are they likely to be in preventing smoking? CNS Drugs. 2001; 15:505-514. (Pubitemid 32735376)
41. Matsushita H, Noguchi M, Tamaki E. Conjugate of bovine serum albumin with nicotine. Biochem Biophys Res Commun. 1974;57:1006-1010.
42. Raupach T, Hoogsteder P, Van Schayck CP. Nicotine vaccines to assist with smoking cessation. Drugs. 2012;72:e1- e16.
43. De Villiers SH, Lindblom N, Kalayanov G, et al. Nicotine hapten structure, antibody selectivity and effect relationship: Result from a nicotine vaccine screening procedure. Vaccine. 2010;28:2161-2168.
44. Lesage MG, Keyler DE, Pentel PR. Current status of immunologic approaches to treating tobacco dependence: Vaccines and nicotinespecific antibodies. American Association of Pharmaceutical Scientists (AAPS) Journal. 2006;8:E65- E75. (Pubitemid 43349386)
45. Hatsukami D, Renard S, Jorenby DE, et al. Safety and immunogenicity of a nicotine conjúgate vaccine in current smokers. Clin Pharmacol Ther. 2005;78:456-467. (Pubitemid 41698900)
46. Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: A randomized controlled trial. Plos One. 2008;3:e2547.
47. Hatsukami DK, Jorenby DE, Gonzales D, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther. 2011;89:392-399.
48. Nabi Biopharmaceuticals Announces Results of First Nicvaxs Phase III Clinical Trial: Smoking Cessation Immunotheraphy Failed to Meet Primary Endpoint. Rockville, MD: Nabi Pharmaceuticals; 2011.